Skip to Main Content

Author Details

Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
2017
31
14
PMIDPaper TitleJournal TitlePublished Year
37676819Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.J Natl Cancer Inst2024
38047392NIPBL::NACC1 Fusion Hepatic Carcinoma.Am J Surg Pathol2024
36796016Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.Blood2023
37919447Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.NPJ Precis Oncol2023
37489101Whole-genome Analysis Elucidates Complex Genomic Events in GLI1 -rearranged Enteric Tumor.Am J Surg Pathol2023
37704749Evolution of structural rearrangements in prostate cancer intracranial metastases.NPJ Precis Oncol2023
37587346Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.Nature2023
37223924Immunogenomic Landscape of Neuroendocrine Prostate Cancer.Clin Cancer Res2023
34676924Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.Adv Mater2022
35644123Weakly-supervised tumor purity prediction from frozen H&E stained slides.EBioMedicine2022
35483877Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.Cold Spring Harb Mol Case Stud2022
36387205Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment.Front Oncol2022
34907080Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.Clin Cancer Res2022
33190043Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.Transl Oncol2021
34518634Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.NPJ Precis Oncol2021
34385567Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.NPJ Precis Oncol2021
34385467Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors.NPJ Genom Med2021
34099734Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.Nat Commun2021
34286887Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.Oncologist2021
34168263Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage.Commun Biol2021
32127465SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.Mol Cancer Ther2020
31959826Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.Nat Commun2020
32091413Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.J Clin Invest2020
33007263Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs.Cell2020
30894499Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.Sci Transl Med2019
31439587PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31525487Clinical features of neuroendocrine prostate cancer.Eur J Cancer2019
30613824BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.JCO Precis Oncol2018
30015382Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.J Pathol2018
29921838Patient derived organoids to model rare prostate cancer phenotypes.Nat Commun2018
28842510Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.Clin Cancer Res2017
  • 1 - 31 of 31

Recommended Authors

Yang Liu
Veracyte inc.
Career Start Year 2019
Number of shared co-authors 15
Sinja Taavitsainen
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2018
Number of shared co-authors 11
Job van Riet
Erasmus MC Cancer Institute
Career Start Year 2017
Number of shared co-authors 0
Vincent Huang
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 5
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 6
Takafumi N Yamaguchi
University of California los angeles
Career Start Year 2015
Number of shared co-authors 7
Daniel H Hovelson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 13
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 18
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 4
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2011
Number of shared co-authors 22
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 12
Kyung Park
New York University Langone Health
Career Start Year 2010
Number of shared co-authors 39
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 31
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 24
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 17
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 20
Elai Davicioni
Veracyte Inc.
Career Start Year 2006
Number of shared co-authors 32
Tamara L Lotan
Johns Hopkins University School of Medicine
Career Start Year 2006
Number of shared co-authors 28
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 4
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 21
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 13
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 47
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 32
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 29
Rohit Mehra
Michigan Center for Translational Pathology.
Career Start Year 2000
Number of shared co-authors 28
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 20
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 9
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 22
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 22
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 40

Collaborators

Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 22
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 21
Olivier Elemento
Meyer Cancer Center
Co-authored papers 19
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 19
Rohan Bareja
Case Western Reserve University
Co-authored papers 9
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 8
David M Nanus
Sandra and Edward Meyer Cancer Center
Co-authored papers 8
Kenneth Eng
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 6
Bishoy M Faltas
Sandra and Edward Meyer Cancer Center
Co-authored papers 5
David Wilkes
Caryl and Israel Englander Institute for Precision Medicine.
Co-authored papers 4
Jenny Xiang
Caryl and Israel Englander Institute for Precision Medicine.
Co-authored papers 4
Nicolas Robine
Sloan-Kettering Institute
Co-authored papers 4
Majd Al Assaad
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 4
Kentaro Ohara
Caryl and Israel Englander Institute for Precision Medicine.
Co-authored papers 4
Ryan Dittamore
Decipher Biosciences Inc.
Co-authored papers 4
Mark A Rubin
University of Bern
Co-authored papers 4
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 4
Loredana Puca
Sandra and Edward Meyer Cancer Center
Co-authored papers 4
David S Rickman
Meyer Cancer Center
Co-authored papers 3
Minita Shah
Co-authored papers 3
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 3
Matti Annala
University of British Columbia
Co-authored papers 3
Ladan Fazli
University of British Columbia
Co-authored papers 3
Alexander W Wyatt
University of British Columbia
Co-authored papers 3
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 2
Shaham Beg
New York-Presbyterian Hospital-Weill Cornell Medical College
Co-authored papers 2
Aram Vosoughi
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 2
Martin E Gleave
University of British Columbia
Co-authored papers 2
Noah Greco
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 2
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Release 1.2